azithromycin Side Effects
Also known as: Zithromax, Z-Pack
Analysis of 37,361 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
37,361
Death-Related
3,628
9.7% of reports
Hospitalizations
14,840
39.7% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 3,628 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 860 |
| DRUG INEFFECTIVE | 477 |
| OFF LABEL USE | 424 |
| PNEUMONIA | 350 |
| DYSPNOEA | 301 |
| RESPIRATORY FAILURE | 286 |
| CONDITION AGGRAVATED | 263 |
| ACUTE KIDNEY INJURY | 260 |
| RENAL FAILURE | 223 |
| CHRONIC KIDNEY DISEASE | 194 |
| HYPOXIA | 188 |
| SEPSIS | 181 |
| CARDIAC ARREST | 177 |
| DRUG INEFFECTIVE FOR UNAPPROVED INDICATION | 164 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 157 |
| HYPOTENSION | 150 |
| ANXIETY | 144 |
| PYREXIA | 132 |
| NAUSEA | 124 |
| FATIGUE | 121 |
Reactions in Hospitalization Reports
Top reactions in 14,840 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| OFF LABEL USE | 1,787 |
| DYSPNOEA | 1,786 |
| DRUG INEFFECTIVE | 1,504 |
| PNEUMONIA | 1,496 |
| PAIN | 1,224 |
| NAUSEA | 1,086 |
| PYREXIA | 1,067 |
| COUGH | 977 |
| ASTHMA | 906 |
| CONDITION AGGRAVATED | 814 |
| DIARRHOEA | 766 |
| VOMITING | 762 |
| FATIGUE | 746 |
| ANXIETY | 737 |
| WHEEZING | 730 |
| HEADACHE | 725 |
| ABDOMINAL PAIN | 658 |
| WEIGHT DECREASED | 650 |
| MALAISE | 633 |
| PULMONARY EMBOLISM | 599 |
Nearby — Related Medications
What the FAERS Data Reveals About azithromycin Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 37,361 voluntary reports linked to azithromycin and its brand equivalents (Zithromax, Z-Pack), spanning 2004 through 2025. Of those, 3,628 (9.7%) listed death as an outcome and 14,840 (39.7%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 59% were female and 40% male; age distribution skews toward 45-64, with 8,126 reports in that bracket. The single most reported reaction is off label use with 3,915 submissions, followed by drug ineffective and dyspnoea.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.